Esketamine Nasal Spray Market Share

North American Market Analysis

The esketamine nasal spray market is anticipated to account for 38% of the revenue share in the coming years. The major factor that is expected to boost the esketamine nasal spray market growth in the region is the increasing prevalence of depressed Americans. A calculated 2 million times each year, people with severe mental health situations are jailed or imprisoned in the U.S. Women are inordinately influenced at twice the rate as men. For this population, detention may worsen pre-existing indications. In fact, while the percentage of U.S. adults getting mental health therapy rose from 19.2% in 2019 to 21.6% in 2021, 42% of U.S. adults with an identifiable situation reported in 2023 that they could not afford to avail the therapy they required. A trio of new studies paints a gloomy picture of how overdose deaths, depression, and obstacles to care are burdening heaviest on unprivileged and minority people - and are arranging to broaden health discrepancies as the U.S. appears from the pandemic.

European Market Forecast

The esketamine nasal spray market in the Europe region is poised to show a notable growth in the upcoming years. The consumption of antidepressant drugs (AD) and esketamine nasal spray has grown drastically in the last two decades in the Europe region The implementation of antidepressants grew by almost two and a half times from 2000 to 2020 in 18 European countries, in line with the Organization for Economic Cooperation and Development (OECD) data. The average antidepressant ingestion around 18 European countries was 30.5 DDD per 1,000 people per day in 2000 increasing to 75.3 DDD in 2020, a 147 per cent rise.  The European Parliament has always been an advocate of the encouragement of good mental health and keeping mental health at the heart of EU managerial. Its Subcommittee on Public Health (SANT) is recently developing its initiative report on mental health.